Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
ASCO-GU – some backing for Pfizer's EZH2 plan
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca heads to the FDA
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
